Efficacy, safety, and tolerability of ansofaxine (LY03005) extended-release tablet for major depressive disorder: a randomized, double-blind, placebo-controlled, dose …
W Mi, F Yang, H Li, X Xu, L Li, Q Tan… - International Journal …, 2022 - academic.oup.com
Abstract Background Ansofaxine (LY03005) extended-release tablet is a potential triple
reuptake inhibitor of serotonin, norepinephrine, and dopamine. This study assessed the …
reuptake inhibitor of serotonin, norepinephrine, and dopamine. This study assessed the …
[HTML][HTML] A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major …
W Mi, X Di, Y Wang, H Li, X Xu, L Li, H Wang… - Translational …, 2023 - nature.com
Major depressive disorder (MDD) is the most prevalent form of depression and is becoming
a great challenge for public health and medical practice. Although first-line antidepressants …
a great challenge for public health and medical practice. Although first-line antidepressants …
[HTML][HTML] Efficacy, tolerability, and safety of toludesvenlafaxine for the treatment of major depressive disorder—A narrative review
O Vasiliu - Pharmaceuticals, 2023 - mdpi.com
The estimated rate of treatment-resistant major depressive disorder (TRD) remains higher
than 30%, even after the discovery of multiple classes of antidepressants in the last 7 …
than 30%, even after the discovery of multiple classes of antidepressants in the last 7 …
Efficacy and safety of agomelatine vs paroxetine hydrochloride in Chinese Han patients with major depressive disorder: a multicentre, double-blind, noninferiority …
YM Yu, KR Gao, H Yu, YF Shen… - Journal of Clinical …, 2018 - journals.lww.com
Purpose The purpose of this study is to investigate the efficacy, safety, and tolerability of
agomelatine and paroxetine in Chinese Han patients with major depressive disorder (MDD) …
agomelatine and paroxetine in Chinese Han patients with major depressive disorder (MDD) …
Efficacy and safety of seltorexant as adjunctive therapy in major depressive disorder: a phase 2b, randomized, placebo-controlled, adaptive dose-finding study
A Savitz, E Wajs, Y Zhang, H Xu… - International Journal …, 2021 - academic.oup.com
Background Seltorexant, a selective antagonist of human orexin-2 receptors, demonstrated
antidepressant effects in a previous exploratory study in patients with major depressive …
antidepressant effects in a previous exploratory study in patients with major depressive …
[HTML][HTML] Efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder: Results of 2 phase 3 …
LA Adler, J Adams, J Madera-McDonough… - Journal of Clinical …, 2022 - journals.lww.com
Purpose/Background: Centanafadine is an inhibitor of norepinephrine, dopamine, and
serotonin reuptake transporters under investigation for the treatment of attention …
serotonin reuptake transporters under investigation for the treatment of attention …
A multicenter, placebo‐controlled, double‐blind, randomized study of efficacy and safety of ocinaplon (DOV 273,547) in generalized anxiety disorder
P Czobor, P Skolnick, B Beer… - CNS neuroscience & …, 2010 - Wiley Online Library
Preclinical studies demonstrated that ocinaplon, a positive allosteric modulator of GABAA
receptors, possesses anxiolytic‐like actions at doses devoid of the side effects typically …
receptors, possesses anxiolytic‐like actions at doses devoid of the side effects typically …
Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo …
JR Calabrese, MA Frye, R Yang… - The Journal of clinical …, 2014 - legacy.psychiatrist.com
Objective: To examine the efficacy and safety of adjunctive armodafinil for major depressive
episodes associated with bipolar I disorder. Method: Adults meeting DSM-IV-TR criteria for …
episodes associated with bipolar I disorder. Method: Adults meeting DSM-IV-TR criteria for …
Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder
TA Ketter, R Yang, MA Frye - Journal of Affective Disorders, 2015 - Elsevier
Background In a previous study, adjunctive armodafinil 150 mg/day significantly improved
depressive symptoms associated with bipolar I disorder. Methods Multicenter, double-blind …
depressive symptoms associated with bipolar I disorder. Methods Multicenter, double-blind …
[HTML][HTML] Open-label trial of acamprosate as a treatment for anxiety
M Hertzman, IS Patt, LA Spielman - Primary Care Companion to …, 2009 - ncbi.nlm.nih.gov
Method. In this small, open-label trial of acamprosate, we treated 21 patients with a clinical
DSM-IV diagnosis of an anxiety disorder, including panic disorder, generalized anxiety …
DSM-IV diagnosis of an anxiety disorder, including panic disorder, generalized anxiety …